Association of serum IgG glycosylation with disease activity of anti-transcription intermediary factor 1 gamma positive dermatomyositis

被引:0
作者
Li, Xi [1 ,2 ,3 ]
Bai, Jingjing [2 ,3 ]
Li, Siting [2 ,3 ]
Li, Mengtao [2 ,3 ]
Zeng, Xiaofeng [2 ,3 ]
Wang, Qian [2 ,3 ,6 ]
Hu, Chaojun [2 ,3 ,4 ,5 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Clin Lab, Nanning, Guangxi, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[3] Minist Educ, Minist Sci & Technol, Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China
[4] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Rheumatol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[5] Minist Educ, Key Lab Rheumatol & Clin Immunol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
[6] Peking Union Med Coll & Chinese Acad Med Sci, Natl Clin Res Ctr Immunol Dis, Dept Rheumatol, Key Lab Rheumatol & Clin Immunol,Minist Educ, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
dermatomyositis; myositis-specific autoantibodies; anti-transcription intermediary factor 1 gamma autoantibodies; glycosylation; disease activity; SINE MYOSITIS; AUTOANTIBODIES; GALACTOSYLATION; SIALYLATION; POLYMYOSITIS; ANTIBODIES; GLYCOFORMS; CLEARANCE; PROFILES; SPECTRUM;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterised by the presence of a variety of myositis-specific autoantibodies (MSA) in the circulation. As one of the commonly-detected MSA, anti-transcription intermediary factor 1 gamma (TIF1 gamma) autoantibody is strongly associated with DM-related malignancy and disease activity. We investigated the glycosylation patterns of serum IgG and to determine the clinical significance of specific glycosylation patterns in patients with anti-TIF1 gamma positive DM.Methods Lectin microarray was used to reveal the glycosylation patterns of serum IgG among 52 DM, 46 disease controls (DC) and 49 healthy controls (HC). Lectin blot was used to further validate the specific alteration of glycosylation. The correlation between glycan levels and clinical features was also evaluated.Results The results of lectin microarray showed that compared with the DC group, the DM group had significantly lower glycan levels of mannose and glucose. Compared with the HC group, the glycans levels of GalNAc, galactose, Gal beta 3GalNAc, sialic acid, and fucose were observed significantly higher in DM group. Lectin blot demonstrated that anti-TIF1 gamma positive DM had lower glycan level of GlcNAc (recognised by LEL) compared to patients with MSA negative DM, DC, and HC groups. Additionally, the glycan level of GlcNAc was positively associated with manual muscle test (r=0.547, p=0.028), or negatively associated with IL-6 level (r=-0.756, p=0.049) and disease activity score (r=-0.507, p=0.045).Conclusion Anti-TIF1 gamma positive DM presents a unique glycosylation pattern in serum IgG. Considering that the glycan level of GlcNAc reflects the inflammatory state and disease activity, glycosylation has a role in clinical utility by monitoring disease in patients with anti-TIF1 gamma positive DM.
引用
收藏
页码:230 / 237
页数:8
相关论文
共 36 条
  • [21] Changes in antibody titres in patients with anti transcription intermediary factor 1-gamma antibody-positive idiopathic inflammatory myositis
    Abe, Yoshiyuki
    Ando, Taiki
    Matsushita, Masakazu
    Tada, Kurisu
    Yamaji, Ken
    Tamura, Naoto
    RHEUMATOLOGY, 2019, 58 (01) : 179 - 181
  • [22] Presence of anti-transcriptional intermediary factor-1 gamma antibodies in a dermatomyositis patient with retroperitoneal cancer of unknown primary site
    Hori, Hiroshi
    Ozeki, Yusuke
    Kobashigawa, Tsuyoshi
    Futsuhara, Kazusige
    Tanaka, Akira
    Watanabe, Eri
    Yabe, Hiroki
    Yago, Toru
    Fukuchi, Takahiko
    Sugawara, Hitoshi
    Kotake, Shigeru
    MODERN RHEUMATOLOGY CASE REPORTS, 2021, 5 (01) : 62 - 68
  • [23] SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-y, and Point Mutation in the Transcription Intermediary Factor 1-y Coding Gene: A Case Report
    Arnon, Johnathan
    Elia, Anna
    Nevo, Yuval
    Lossos, Alexander
    Nechushtan, Hovav
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (09):
  • [24] Identification of distinct cytokine/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-gamma antibody
    Zhao, Qian
    Chen, Yongheng
    Diao, Licheng
    Zhang, Shimin
    Wu, Dan
    Xue, Feng
    Xia, Qunli
    Li, Hao
    Zheng, Jie
    Cao, Hua
    RHEUMATOLOGY, 2022, 61 (05) : 2176 - 2184
  • [25] Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis
    Fujimoto, Manabu
    Murakami, Akihiro
    Kurei, Shunsuke
    Okiyama, Naoko
    Kawakami, Atsushi
    Mishima, Michiaki
    Sato, Shinji
    Seishima, Mariko
    Suda, Takafumi
    Mimori, Tsuneyo
    Takehara, Kazuhiko
    Kuwana, Masataka
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2016, 84 (03) : 272 - 281
  • [26] Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis
    Kotobuki, Yorihisa
    Tonomura, Kyoko
    Fujimoto, Manabu
    IMMUNOLOGICAL MEDICINE, 2021, 44 (01) : 23 - 29
  • [27] Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis
    Kato, Toshio
    Ito, Satoru
    Tsuzuki, Toyonori
    Watanabe, Daisuke
    Kubo, Akihito
    Yamaguchi, Etsuro
    RESPIROLOGY CASE REPORTS, 2019, 7 (04):
  • [28] Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis
    Best, Marion
    Molinari, Nicolas
    Chasset, Francois
    Vincent, Thierry
    Cordel, Nadege
    Bessis, Didier
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (03) : 256 - 262
  • [29] Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis
    Krystufkova, Olga
    Hulejova, Hana
    Mann, Herman F.
    Pecha, Ondrej
    Putova, Ivana
    Ekholm, Louise
    Lundberg, Ingrid E.
    Vencovsky, Jiri
    ARTHRITIS RESEARCH & THERAPY, 2018, 20
  • [30] Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report
    Kim, Yoonjoo
    Park, Dongil
    Choi, Song-Yi
    Chung, Chaeuk
    THORACIC CANCER, 2022, 13 (19) : 2808 - 2811